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Eptiﬁbatide
(n = 561)
Abciximab
(n = 1522) p value
Age 63.8814.1 62.1016.1 0.098
Gender (female) 139 (24.8%) 349(22.9%) 0.382
Previous MI 89(15.9%) 189(12.8%) 0.071
Previous CABG 23(4.1%) 40(2.7%) 0.114
Previous PCI 72 (12.8%) 139 (9.4%) 0.028
Hypercholesterolaemia 298 (53.1%) 462 (42.4%) <0.001
Hypertension 261(46.5%) 615(45.0%) 0.546
DM 93(18.0%) 268(17.8%) 0.947
eGFR<60 112(19.9%) 315 (20.7%) 0.851
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Background: Premature discontinuation of clopidogrel after drug-eluting stent (DES)
implantation increases the risk of adverse cardiac events. Factors associated with
premature discontinuation, however, are poorly understood.
Methods: Patients who discontinued clopidogrel before 1 year after percutaneous
coronary intervention (PCI) with DES were compared to patients who continued
clopidogrel for at least 1 year in this retrospective cohort study. Patients with
cardiogenic shock were excluded. Reasons for discontinuation of clopidogrel were
also collected. Insurance was categorized as private, Medicare, Medicaid, and unin-
sured. Multivariable logistic regression, stratiﬁed by age 65 years, was performed to
identify socioeconomic and clinical factors independently associated with premature
(<1 year) clopidogrel discontinuation.
Results: Among 4841 patients that received DES, 21.9% discontinued clopidogrel
before 1 year. The most common reasons for clopidogrel discontinuation were
physician decision (56.9%) and bleeding (16.9%). Overall, 53.8% of patients had
private insurance, 42.1% Medicare, 2.9% Medicaid, and 1.2% were uninsured.
Median household income by population was not associated with premature discon-
tinuation in the overall cohort. Among the population <65 years, patients with
Medicare, lack of insurance, major bleeding, and history of PCI or congestive heart
failure were more likely to discontinue clopidogrel prematurely. For the population
65 years, patients on warfarin therapy or with history of PCI were more likely, and
patients with history of hypertension or CABG were less likely, to discontinue clo-
pidogrel prematurely (Table).Age <65 Age 65
Odds ratio 95% CI p value Odds ratio 95% CI p value
Medicare 1.64 1.06-2.53 0.03 1.04 0.77-1.42 0.78
Medicaid 1.04 0.55-1.97 0.89 1.02 0.24-4.27 0.98
Uninsured 3.37 1.66-6.85 <0.001 N/A N/A N/A
African-
American
1.24 0.91-1.69 0.17 1.2 0.91-1.60 0.2
Warfarin 0.95 0.49-1.87 0.89 1.86 1.26-2.75 0.002
Major
bleeding
3.68 1.11-12.1 0.03 2.8 0.73-10.7 0.13
Hematocrit
(per 5%)
1.01 0.95-1.08 0.71 0.88 0.77-1.00 0.05
Male 1.23 0.91-1.67 0.18 1.01 0.77-1.32 0.95
Acute
Coronary
Syndrome
1.12 0.76-1.64 0.58 1.29 0.89-1.89 0.18
Previous PCI 1.75 1.33-2.31 <0.001 1.38 1.07-1.78 0.01
Previous
CABG
0.9 0.62-1.30 0.56 0.73 0.54-0.98 0.04
Hypertension 0.86 0.59-1.24 0.41 0.64 0.44-0.92 0.02
Congestive
heart failure
1.76 1.16-2.68 0.008 1.36 0.96-1.91 0.08
MV disease 315(56.6%) 809(57.3%) 0.686
Card Shock 29(5.2%) 94(6.3%) 0.404
Access (radial) 339 (60.5%) 722(48.3%) <0.001
Procedural Success 524 (93.4%) 1407(92.4%) 0.139Conclusions: Premature discontinuation of clopidogrel is common among patients
undergoing PCI with DES and is often secondary to physician decision rather than
noncompliance. Premature discontinuation is associated with both insurance status
and clinical factors.
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Background: Glycoprotein IIb/IIIa inhibitors are recommended by guidelines in
patients with ST-segment elevation myocardial infarction (STEMI) treated with
primary percutaneous coronary intervention (PPCI). There are few studies directlyB48 JACC Vol 62/18/Suppl B j October 27–Novemcomparing these two agents. The aim of this study was to compare the effectiveness of
eptiﬁbatide relative to abciximab in patients with STEMI treated with PPCI.
Methods: This was an observational cohort study of 2083 patients who received
a GPIIb/IIIa inhibitor whilst undergoing primary percutaneous coronary intervention
(PPCI) from 2006 to 2012. Patients who did not receive a GPIIb/IIIa inhibitor were
excluded. The primary end-point was the ﬁrst major adverse cardiac event (MACE)
deﬁned as death, non-fatal myocardial infarction, stroke or target vessel
revascularisation.
Results: 1522 patients received abciximab and 561 received eptiﬁbatide. Differences
in baseline characteristics are outlined in Table 1. Patients receiving eptiﬁbatide had
higher rates of previous PCI and hypercholesterolaemia and were more likely to
undergo a procedure from the radial route. Unadjusted Kaplan-Meier analysis revealed
no signiﬁcant difference in 1-year event rates between patients given eptiﬁbatide
versus abciximab. Age-adjusted Cox analysis demonstrated no difference in 1 year
outcome between abciximab and eptiﬁbatide (HR 1.01 [95% CI 0.73-1.39]), which
persisted after multivariate adjustment (HR 1.37 [95% CI 0.93-1.96]). Regression
adjustment incorporating a propensity score (age, gender, ethnicity, previous MI, PCI
or CABG, diabetes, hypertension, hypercholesterolaemia, smoking status, presence or
absence of shock, and ejection fraction) into the hazards model as a covariate, showed
no difference in outcome (HR 1.21 [95% CI 0.83-1.54]).Conclusions: This observational data suggests eptiﬁbatide is associated with similar
outcomes to abciximab in patients with STEMI undergoing PPCI.
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Background: Patients undergoing stent implantation with high platelet reactivity
(HPR) on clopidogrel have a greater incidence of adverse ischemic events. However,
low HPR may increase major bleeding, which can also inﬂuence mortality.
Methods: ADAPT-DES was an 8,583 pt prospective, multicenter study of pts
receiving DES; routine platelet function testing (VerifyNow) was performed following
clopidogrel loading. We sought to characterize the association between HPR and stent
thrombosis (ST) and major bleeding at 1 year by separating pts into quintiles of HPR.
Results: The median PRU of the 5 quintiles was 57, 130, 187, 244, and 317
respectively (most to least reactive); 42.7% of patients had HPR as deﬁned by
PRU>208. HPR was associated with 1-year ST (1.3% vs. 0.5%, p¼0.0001), but was
also protective from major bleeding (5.6% vs. 6.7%, p¼0.04); both types of events
were independent predictors of 1-year mortality. There was a graded association
between PRU quintiles and ST (Table), whereas for major bleeding, the highest risk
occurred in the lowest PRU quintile, a ﬁnding that was signiﬁcant in multivariableber 1, 2013 j TCT Abstracts/POSTER/Antiplatelets and Antithrombins
